Literature DB >> 22383132

Assessment of dementia risk in aging adults using both FDG-PET and FDDNP-PET imaging.

L M Ercoli1, G W Small, P Siddarth, V Kepe, S-C Huang, K J Miller, H Lavretsky, S Y Bookheimer, J R Barrio, D H S Silverman.   

Abstract

BACKGROUND: In a previous study, positron emission tomography (PET) with 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP), a molecule that binds to plaques and tangles in vitro, identified three subgroups of non-demented subjects according to FDDNP binding patterns: low global (LG) binding; high frontal, parietal, medial temporal binding (HF/PA); and high medial and lateral temporal and posterior cingulate (HT/PC) binding. In this follow-up investigation, we compared 2-deoxy-2-[F-18]fluoro- d-glucose (FDG)-PET cerebral metabolic patterns in the three FDDNP-PET binding subgroups.
METHODS: Fifty-four subjects with normal aging (N = 28) or amnestic forms of mild cognitive impairment (N = 26) underwent FDDNP-PET and FDG-PET scanning. Subjects in the LG, HF/PA, and HT/PC FDDNP subgroups were compared according to visual ratings, statistical parametric mapping, and automated region of interest analyses of their FDG-PET data.
RESULTS: The FDDNP-PET subgroups demonstrated different glucose metabolic patterns according to visual ratings, region of interest, and statistical parametric mapping analyses of FDG-PET data. The LG FDDNP subgroup showed no areas of significant hypometabolism relative to the other subgroups and had low Alzheimer's disease risk by FDG-PET standards. The HF/PA FDDNP subgroup demonstrated hypometabolism in bilateral inferior parietal/parietotemporal, bilateral posterior cingulate, perisylvian, mid-temporal gyrus, and dorsolateral prefrontal regions, which is a pattern suggestive of high Alzheimer's disease risk. The HT/PC FDDNP subgroup demonstrated heterogeneous FDG-PET patterns with predominant anterior frontal and anterior temporal hypometabolism, suggestive of mixed etiologies, including fronto-temporal dementia risk.
CONCLUSIONS: The FDG-PET data provided independent validation that different patterns of FDDNP-PET binding in non-demented individuals may be associated with differential dementia risk.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22383132      PMCID: PMC4263269          DOI: 10.1002/gps.2816

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  49 in total

1.  PET of brain amyloid and tau in mild cognitive impairment.

Authors:  Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

2.  Construction of a (18)F-FDG PET normative database of Japanese healthy elderly subjects and its application to demented and mild cognitive impairment patients.

Authors:  Eizo Iseki; Norio Murayama; Ryoko Yamamoto; Hiroshige Fujishiro; Masaru Suzuki; Masato Kawano; Shuya Miki; Kiyoshi Sato
Journal:  Int J Geriatr Psychiatry       Date:  2010-04       Impact factor: 3.485

3.  Neuropathologic features of amnestic mild cognitive impairment.

Authors:  Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Kris A Johnson; David S Knopman; Bradley F Boeve; Gregory A Jicha; Robert J Ivnik; Glenn E Smith; Eric G Tangalos; Heiko Braak; Emre Kokmen
Journal:  Arch Neurol       Date:  2006-05

4.  Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment.

Authors:  Matthias H Tabert; Jennifer J Manly; Xinhua Liu; Gregory H Pelton; Sara Rosenblum; Marni Jacobs; Diana Zamora; Madeleine Goodkind; Karen Bell; Yaakov Stern; D P Devanand
Journal:  Arch Gen Psychiatry       Date:  2006-08

5.  High-yield, automated radiosynthesis of 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([18F]FDDNP) ready for animal or human administration.

Authors:  Jie Liu; Vladimir Kepe; Alenka Zabjek; Andrej Petric; Henry C Padgett; Nagichettiar Satyamurthy; Jorge R Barrio
Journal:  Mol Imaging Biol       Date:  2007 Jan-Feb       Impact factor: 3.488

6.  Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss.

Authors:  A Bozoki; B Giordani; J L Heidebrink; S Berent; N L Foster
Journal:  Arch Neurol       Date:  2001-03

7.  Gender differences in cerebellar metabolism: test-retest reproducibility.

Authors:  N D Volkow; G J Wang; J S Fowler; R Hitzemann; N Pappas; K Pascani; C Wong
Journal:  Am J Psychiatry       Date:  1997-01       Impact factor: 18.112

8.  Two-year outcome of MCI subtypes and aetiologies in the Göteborg MCI study.

Authors:  Arto Nordlund; Sindre Rolstad; Ola Klang; Ake Edman; Stefan Hansen; Anders Wallin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-12-03       Impact factor: 10.154

9.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501

Review 10.  Neuropathologic alterations in mild cognitive impairment: a review.

Authors:  William R Markesbery
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

View more
  2 in total

Review 1.  Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimer's disease.

Authors:  Mak Adam Daulatzai
Journal:  J Neural Transm (Vienna)       Date:  2015-05-06       Impact factor: 3.575

2.  A Hierarchical Bayesian Model for the Identification of PET Markers Associated to the Prediction of Surgical Outcome after Anterior Temporal Lobe Resection.

Authors:  Sharon Chiang; Michele Guindani; Hsiang J Yeh; Sandra Dewar; Zulfi Haneef; John M Stern; Marina Vannucci
Journal:  Front Neurosci       Date:  2017-12-05       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.